The 2023 Annual Meeting of American Academy of Dermatology Association was held from 17 to 21 March 2023 in New Orleans, Louisiana, United States. As one of the largest, most influential

Stevanato Group S.p.A. a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced

DelSiTech Ltd, a Finnish drug delivery and drug development company, today announces that it has been awarded a grant from the Bill & Melinda Gates Foundation to develop

Labstat Inc., A Certified Group Company, has entered into a partnership with Toxys to offer the ToxTracker assay at its Kitchener, Ontario laboratory. ToxTracker is a state-of-the-art stem

Optimism is on the rise as the American Cancer Society is reporting that the five-year survival rate for those diagnosed with pancreatic has increased to 12%—representing an increase of 1% over

Nippon Express a group company of NIPPON EXPRESS HOLDINGS, INC., became the first Japanese forwarder to join Pharma.Aero on January 25 this year.

On March 7th, 2023, Suzhou Porton Advanced Solutions Ltd. and Bennu Biotherapeutics announced a strategic partnership to advance cell and gene therapy R&D pipelines.

Astellas Pharma Inc. today announced positive topline results from the Phase 3 China ARCHES study of XTANDI® plus androgen deprivation therapy in men with metastatic hormone-sensitive

Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the first generic version of Allergan's Pylera® 140 mg, 125 mg and 125

Sumitovant Biopharma Ltd.and Myovant Sciences Ltd. announced today that Sumitovant has successfully completed its acquisition of Myovant originally announced October 23, 2022.

Shuttle Pharmaceuticals Holdings, Inc.a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with

Microbion Corporation today announced that a Phase 2, randomized, controlled study has been initiated to assess the safety and efficacy of topical pravibismane for the treatment of subjects

InvoX Pharma Limited a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited with an advancing pipeline of innovative products, today announces that it has successfully

On the eve of International Women’s Day, BioSyent Inc. celebrates the Canadian launch of FeraMAX® Pd Maintenance 45 by its subsidiary, BioSyent Pharma Inc. FeraMAX® Pd

IBSA Pharma announced today that it has entered into an agreement with Mark Cuban Cost Plus Drug Company, PBC to offer Tirosint® oral capsules at a low cash price via the Cost Plus Drugs

Harbour BioMed a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology,

Sun Pharmaceutical Industries Limited today announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical

The pioneer of innovative proteomic and glycomic research solutions, today announced the acquisitions of Click Chemistry Tools, a manufacturer of click chemistry linkers and labeling

Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is opening a new office in Cambridge Innovation Centre, CIC, marking a new era towards the company's rising ambition on serving and collaborating with world's best biotech start-ups and ventures.

Finding easy-to-understand information about pediatric liver diseases that even kids can relate to has been a challenge, that's why the American Liver Foundation is launching a new pediatric liver

ArisGlobal , the leading provider of life sciences software that automates the core functions of drug development with its end-to-end LifeSphere® LifeSphere® technology platform, today announced

The ERP Biomarker Qualification Consortium announced today the successful completion of a pharma industry-sponsored study to measure the electrophysiologic effects of ketamine on healthy brain function.

NATCO Pharma Limited announces launch of Pomalidomide Capsules in Canada, the first generic alternative to POMALYST® brand in the country approved by Health Canada. Pomalidomide is used in combination with Dexamethasone and Bortezomib for the treatment of adult patients

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a multi-year, strategic collaboration with Pfizer in which the two companies are working together to further AI and machine learning-driven efforts in therapeutic development. The goal of this collaboration

Mitsubishi Tanabe Pharma America, Inc. today announced the publication of results from the global, multi-center, open-label, Phase 3 clinical trial evaluating the long-term safety

AMO Pharma Limited, a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, today announced that the UK

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. (“Ono”), for CUE-401, a bispecific protein

TransCode Therapeutics, Inc., the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the signing of a non-binding letter of intent and a joint research and development agreement (JDA) with industrial biotechnology and genome editing expert, BRAIN Biotech AG

MMS Holdings, a data-focused contract research organization (CRO) – announced its partnership with the Institute for Advanced Clinical Trials (I-ACT) to accelerate the development of life-saving therapeutics, including vaccines, medicines, and medical devices for children.

Pharmatech Associates today announced a strategic alliance that brings PCM expertise and capabilities to the marketplace to tackle drug shortages and supply chain issues by providing drug sponsors and manufacturers a more effective means of making finished drug products

Biocytogen Pharmaceuticals Co., Ltd. today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines

NS Pharma, Inc. announced today the first patient enrollment in a Phase 2 clinical study of NS-018 an investigational treatment for myelofibrosis a rare and incurable blood cancer.

Theragent, a cell therapy CDMO focused on advancing next-generation cancer and rare disease treatments, has signed a multi-year exclusive contract with Insight68, an AI-driven software provider

National Resilience, Inc., a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced a 10-year biomanufacturing partnership with a leading pharmaceutical company for its portfolio of services across Process and Analytical Development, Drug Substance, and Drug Product manufacturing

Renexxion Ireland Limited, a private biopharmaceutical company committed to providing innovative medicines to patients with high unmet need for gastrointestinal disorders, will is pleased to

Taiwan-based Formosa Pharmaceuticals announced today that the company has entered into a collaboration agreement with Eyenovia, Inc. for the development of novel ophthalmic therapeutics.

GreenLab, Inc. announces launch of the biotech startup's proprietary vector technology platform. GreenLab Vector Technology greens recombinant protein manufacturing by transforming novel

ESSA Pharma Inc. a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that further analyses of initial clinical data

As federal authorities widen a multistate investigation into antibiotic-resistant Pseudomonas aeruginosa bacterial contamination linked to EzriCare Artificial Tears eye drops, a woman has now filed a federal lawsuit against EzriCare and retailer Walmart after using the eye drops and suffering

PharmaNutra S.p.A. a company specialised in mineral and iron-based nutritional supplements and medical devices for muscles and joints, is ready to face the great challenge of the FIA World

Astellas Pharma Inc. today announced its commitment to achieve net zero greenhouse gas emissions by 2050.Astellas Pharma Inc. today announced its commitment to achieve net zero greenhouse gas emissions by 2050.

Roche today announced that it has expanded its collaboration with Janssen Biotech Inc. to create companion diagnostics for targeted therapies, further strengthening research and innovation activities.

Envision Pharma Group a leading global technology-enabled commercialization, integrated medical capabilities and solutions, and data analytics partner to the life sciences industry, announced

Kenya Medical Research Institute NEC Corporation and Nagasaki University have developed an immunization management system based on digital biometrics for newborns in Kenya. Validation

Seqens Group, an integrated leader in the development and manufacture of active pharmaceutical ingredients (APIs) and intermediates, today announced that it has opened Seqens Boston R&D Center, a state-of-the-art, 15,000 square-foot R&D center in Devens, Mass. Serving as one of the company’s global centers

Ellipses Pharma, a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for EP0042

Ajinomoto Co., Inc.today announced a license agreement with Exelixis, Inc. to develop AJICAP , its proprietary site-specific bioconjugation and Linker Technology of Ajinomoto Co., in the development of certain Exelixis Antibody-Drug Conjugate programs.Exelixis is a commercially successful Exelixis is a commercially successful

Hemab Therapeutics, a clinical-stage biotechnology company developing next-generation therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the first patient has been dosed in a Phase 1/2 study evaluating HMB-001 for the treatment of the severe bleeding disorder Glanzmann